Smith & Nephew SNATS Stock-Based Compensation 2010-2025 | SNN

Smith & Nephew SNATS stock-based compensation for the twelve months ending June 30, 2025 was $0M, a 0% increase year-over-year.

  • Smith & Nephew SNATS annual stock-based compensation for 2024 was $0.04B, a 2.56% increase from 2023.
  • Smith & Nephew SNATS annual stock-based compensation for 2023 was $0.039B, a 2.5% decline from 2022.
  • Smith & Nephew SNATS annual stock-based compensation for 2022 was $0.04B, a 2.44% decline from 2021.

Smith & Nephew SNATS Stock-Based Compensation 2010-2025 | SNN

  • Smith & Nephew SNATS annual stock-based compensation for 2024 was $0.04B, a 2.56% increase from 2023.
  • Smith & Nephew SNATS annual stock-based compensation for 2023 was $0.039B, a 2.5% decline from 2022.
  • Smith & Nephew SNATS annual stock-based compensation for 2022 was $0.04B, a 2.44% decline from 2021.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$229B
Boston Scientific (BSX)$157.6B
Stryker (SYK)$150.8B
EssilorLuxottica (ESLOY)$144B
Medtronic (MDT)$118.3B
Lonza Group Ag (LZAGY)$50.6B
Haleon (HLN)$43.2B
ResMed (RMD)$41.8B
GE HealthCare Technologies (GEHC)$33.8B
Agilent Technologies (A)$33.6B
Koninklijke Philips (PHG)$26.8B
Terumo (TRUMY)$26.5B
Insulet (PODD)$23.4B
Zimmer Biomet Holdings (ZBH)$21.3B
Baxter (BAX)$12.6B
Sunny Optical Technology (SNPTF)$10.8B
Demant (WILYY)$8.1B
Bio-Rad Laboratories (BIO)$8B
Lantheus Holdings (LNTH)$3.8B
Envista Holdings (NVST)$3.5B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Prestige Consumer Healthcare (PBH)$3.3B
Perrigo (PRGO)$3.3B
ICU Medical (ICUI)$3.1B
Haemonetics (HAE)$2.7B
LeMaitre Vascular (LMAT)$2.2B
Acuren (TIC)$2.2B
Curaleaf Holdings (CURLF)$2.1B
QuidelOrtho (QDEL)$1.9B
Green Thumb Industries (GTBIF)$1.9B